INFLUENCE OF ADDING ZINC ARGINYLE-GLYCINATE TO IMPROVE EFFICACY OF BIOREGULATORY PEPTIDES OF THE PROSTATE GLAND IN TREATMENT OF PATIENTS WITH IMPAIRED SPERM PARAMETERS.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The aim of this study was to analyze the positive effect of adding ZAG to the drug in patients with impaired spermatogenesis.

Why It Was Studied

A total of 98 men aged 25-45 years (an average of 35.2±4.3 years) with a verified diagnosis of chronic abacterial prostatitis and related reproductive dysfunctions in the phase III, randomized, multicenter, open-label clinical trial was examined.

The duration of participation of patients in the study was 14-16 days, the screening period was 2-3 days, the duration of therapy was 10 days, and the final examination was 2-3 days.

Who Took Part

The abstract describes 98 men taking part.

PubMed tags the participants as men only.

How the Study Was Run

The design is described as randomized, open-label and multicenter.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the men and staff both knew the treatment.

More than one site took part, so the men came from several places.

What Was Measured

Topics PubMed links to this paper include Sperm Motility, Prostate, Prostatitis, Semen, Suppositories, Teratozoospermia and Spermatozoa.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Vitamin D, K2, Magnesium and Zinc in 98 men.

The publication is from 2022 (Georgian medical news), a journal based in Georgia (Republic).

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.